知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

39 条记录 (耗时 0.029 秒)

    MEDICAMENTS COMPRISING GENE RECOMBINANT ANTIBODY AGAINST GANGLIOSIDE GD3
    21.
    发明申请
    MEDICAMENTS COMPRISING GENE RECOMBINANT ANTIBODY AGAINST GANGLIOSIDE GD3 审中-公开
    含有抗坏血酸GD3基因重组抗体的药物

    公开(公告)号：US20090226399A1

    公开(公告)日：2009-09-10

    申请号：US12420142

    申请日：2009-04-08

    申请人： Kenya Shitara ,  Rinpei Niwa ,  Junji Kanazawa ,  Masao Asada

    发明人： Kenya Shitara ,  Rinpei Niwa ,  Junji Kanazawa ,  Masao Asada

    IPC分类号： A61K39/395 ,  A61K38/21 ,  A61P35/00

    CPC分类号： C07K16/28 ,  A61K39/39558 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/732 ,  C07K2317/734 ,  A61K2300/00

    摘要： In order to obtain high therapeutic effects in treating malignant tumors, particularly melanoma, a new therapeutic method having less side effects, or a new therapeutic method which can provide further high therapeutic effects at conventional doses of agents has been desired.An object of the present invention is to provide a medicament which can provide higher therapeutic effects than any one of a gene recombinant antibody against ganglioside GD3 or the antibody fragment thereof alone, and a substance which activates an immunocomponent cell and a substance having an antitumor activity alone, by combining a gene recombinant antibody against ganglioside GD3 or the antibody fragment thereof with at least one of a substance which activates an immunocomponent cell and a substance having an antitumor activity. Also, the medicament is expected to relieve side effects which were problems in the case of administration of individual single agents.

    摘要翻译： 为了在治疗恶性肿瘤，特别是黑素瘤中获得高治疗效果，期望具有较少副作用的新治疗方法或可以在常规剂量的试剂中提供更高治疗效果的新治疗方法。 本发明的目的是提供一种可以提供比单独的针对神经节苷脂GD3的基因重组抗体或其单独的抗体片段的任何一种更高的治疗效果的药物，以及激活免疫组分细胞的物质和具有抗肿瘤活性的物质 通过将基因重组抗体与神经节苷脂GD3或其抗体片段与激活免疫组分细胞的物质和具有抗肿瘤活性的物质中的至少一种组合。 此外，预期药物可以减轻在给予单个单一药剂的情况下是问题的副作用。

    Antibody against human insulin-like growth factor
    22.
    发明授权
    Antibody against human insulin-like growth factor 有权
    抗人类胰岛素样生长因子的抗体

    公开(公告)号：US07438911B2

    公开(公告)日：2008-10-21

    申请号：US10513148

    申请日：2003-04-30

    申请人： Kenya Shitara ,  Kazuyasu Nakamura ,  Akiko Furuya ,  Rinpei Niwa ,  Yuji Ohki ,  Nobuo Hanai

    发明人： Kenya Shitara ,  Kazuyasu Nakamura ,  Akiko Furuya ,  Rinpei Niwa ,  Yuji Ohki ,  Nobuo Hanai

    IPC分类号： A61K39/395 ,  G01N33/53 ,  C12N5/06 ,  C12N15/00 ,  C12P21/08 ,  C07K16/22

    CPC分类号： C07K16/22 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92

    摘要： For the effective treatment of diseases such as cancer in which hIGF participates, there have been desired to be developed antibodies which strongly bind to both factors hIGF-I and hIGF-II and inhibit their functions and fragments of these antibodies. The present invention provides antibodies which have the ability to specifically bind to human IGF-I and IGF-II to thereby inhibit the functions of human IGF-I and IGF-II and have binding activity with a binding constant of 5×109 M−1 or more measured with a biosensor BIACORE. In addition, the present invention provides diagnostics, preventives and remedies for an hIGF-mediated disease and a disease showing pathological progressing due to abnormally promoted hIGF production, which use said antibodies.

    摘要翻译： 为了有效治疗诸如hIGF参与的癌症的疾病，期望开发出与hIGF-1和hIGF-II两者强烈结合并抑制其功能和这些抗体片段的抗体。 本发明提供具有特异性结合人IGF-I和IGF-II从而抑制人IGF-I和IGF-II的功能并具有结合常数为5×10 9的结合活性的抗体， 或者用生物传感器BIACORE测量的更高/更高。 此外，本发明提供了hIGF介导的疾病的诊断，预防措施和补救措施以及由于异常促进的hIGF产生导致使用所述抗体的病理进展的疾病。

    Method for Treating CCR4-Related Diseases
    23.
    发明申请
    Method for Treating CCR4-Related Diseases 审中-公开
    治疗CCR4相关疾病的方法

    公开(公告)号：US20080213266A1

    公开(公告)日：2008-09-04

    申请号：US11969555

    申请日：2008-01-04

    申请人： Shigeru Iida ,  Mitsuo Satoh ,  Miho Urakubo ,  Masako Wakitani ,  Kazuhisa Uchida ,  Rinpei Niwa ,  Kenya Shitara

    发明人： Shigeru Iida ,  Mitsuo Satoh ,  Miho Urakubo ,  Masako Wakitani ,  Kazuhisa Uchida ,  Rinpei Niwa ,  Kenya Shitara

    IPC分类号： A61K39/395 ,  A61P43/00

    CPC分类号： C07K16/2866 ,  C07K2317/41 ,  C07K2317/732

    摘要： The present invention provides an antibody composition comprising an antibody molecule which specifically binds to human CC chemokine receptor 4 (CCR4) and has complex type N-glycoside-linked sugar chains in the Fc region, wherein the complex type N-glycoside-linked sugar chains have a structure in which fucose is not bound to N-acetylglucosamine in the reducing end in the sugar chains; a transformant which produces the antibody composition; a process for producing the antibody composition; and a pharmaceutical composition comprising the antibody composition.

    摘要翻译： 本发明提供一种抗体组合物，其包含特异性结合人类CC趋化因子受体4（CCR4）的抗体分子，并且在Fc区具有复合型N-糖苷连接的糖链，其中复合型N-糖苷连接的糖链 在糖链的还原端具有岩藻糖不与N-乙酰葡糖胺结合的结构; 产生抗体组成的转化体; 制备抗体组合物的方法; 和包含该抗体组合物的药物组合物。

    MEDICAMENTS COMPRISING GENE RECOMBINANT ANTIBODY AGAINST GANGLIOSIDE GD3
    24.
    发明申请
    MEDICAMENTS COMPRISING GENE RECOMBINANT ANTIBODY AGAINST GANGLIOSIDE GD3 审中-公开
    含有抗坏血酸GD3基因重组抗体的药物

    公开(公告)号：US20080166345A1

    公开(公告)日：2008-07-10

    申请号：US12033516

    申请日：2008-02-19

    申请人： Kenya SHITARA ,  Rinpei Niwa ,  Junji Kanazawa ,  Masao Asada

    发明人： Kenya SHITARA ,  Rinpei Niwa ,  Junji Kanazawa ,  Masao Asada

    IPC分类号： A61K39/395 ,  A61P35/04

    CPC分类号： C07K16/28 ,  A61K39/39558 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/732 ,  C07K2317/734 ,  A61K2300/00

    摘要： In order to obtain high therapeutic effects in treating malignant tumors, particularly melanoma, a new therapeutic method having less side effects, or a new therapeutic method which can provide further high therapeutic effects at conventional doses of agents has been desired.An object of the present invention is to provide a medicament which can provide higher therapeutic effects than any one of a gene recombinant antibody against ganglioside GD3 or the antibody fragment thereof alone, and a substance which activates an immunocomponent cell and a substance having an antitumor activity alone, by combining a gene recombinant antibody against ganglioside GD3 or the antibody fragment thereof with at least one of a substance which activates an immunocomponent cell and a substance having an antitumor activity. Also, the medicament is expected to relieve side effects which were problems in the case of administration of individual single agents.

    摘要翻译： 为了在治疗恶性肿瘤，特别是黑素瘤中获得高治疗效果，期望具有较少副作用的新治疗方法或可以在常规剂量的试剂中提供更高治疗效果的新治疗方法。 本发明的目的是提供一种可以提供比单独的针对神经节苷脂GD3的基因重组抗体或其单独的抗体片段的任何一种更高的治疗效果的药物，以及激活免疫组分细胞的物质和具有抗肿瘤活性的物质 通过将基因重组抗体与神经节苷脂GD3或其抗体片段与激活免疫组分细胞的物质和具有抗肿瘤活性的物质中的至少一种组合。 此外，预期药物可以减轻在给予单个单一药剂的情况下是问题的副作用。

    Antibody variants composition
    28.
    发明授权
    Antibody variants composition 有权
    抗体变体组成

    公开(公告)号：US09556279B2

    公开(公告)日：2017-01-31

    申请号：US13038576

    申请日：2011-03-02

    申请人： Rinpei Niwa ,  Mami Tsuchiya

    发明人： Rinpei Niwa ,  Mami Tsuchiya

    IPC分类号： C07K16/00 ,  C07K16/28

    CPC分类号： C07K16/2887 ,  C07K2317/21 ,  C07K2317/41 ,  C07K2317/522 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92

    摘要： Among N-glycoside-linked sugar chains which are bound to the Fc region of an antibody, sugar chains which are bound to Asn at position 297 relates to the activity and stability of the antibody in blood, but there is a possibility that extra sugar chains bound to the amino acid residues at positions other than 297 have influences upon the antibody constant region-mediated activity and a possibility of causing a problem of uniformity as a therapeutic antibody preparation. Accordingly, among N-glycoside-linked sugar chains which bind to the Fc region of the antibody, a method for controlling extra sugar chains which are bound to Asn residues at positions other than position 297 according to the EU index is required. The present invention provides an antibody variant composition, comprising amino acid residues of an Asn-X-Ser/Thr (X represents an amino acid residue other than Pro) sequence at positions other than positions 297 to 299 according to the EU index in an Fc region of a human IgG antibody, in which at least one amino acid substitution selected from an amino acid substitution of Asn to other amino acid residue, an amino acid substitution of X to Pro and an amino acid substitution of Ser/Thr to other amino acid residue is carried out, and a fragment of the antibody variant composition.

    摘要翻译： 在与抗体的Fc区结合的N-糖苷连接的糖链中，在297位与Asn结合的糖链涉及抗体在血液中的活性和稳定性，但存在额外的糖链 与297以外的位置相连的氨基酸残基对抗体恒定区介导的活性有影响，可能导致作为治疗性抗体制剂的均匀性问题。 因此，在与抗体的Fc区结合的N-糖苷连接的糖链中，需要根据EU指数控制除位置297以外的Asn残基的额外糖链的方法。 本发明提供一种抗体变体组合物，其包含Asn-X-Ser / Thr（X代表除Pro之外的氨基酸残基）的氨基酸残基，其位置不同于位置297至299，根据Fc指数中的EU指数 区域，其中至少一个氨基酸取代选自Asn的氨基酸取代至其它氨基酸残基，X至Pro的氨基酸取代和Ser / Thr对其它氨基酸的氨基酸取代 进行残基和抗体变体组合物的片段。

    ANTI-CD4 ANTIBODY
    29.
    发明申请
    ANTI-CD4 ANTIBODY 有权
    抗CD4抗体

    公开(公告)号：US20130177944A1

    公开(公告)日：2013-07-11

    申请号：US13755472

    申请日：2013-01-31

    申请人： Tomoaki NAKAGAWA ,  Sayaka HORI ,  Rinpei NIWA ,  Tsuguo KUBOTA ,  Kazuhiro MASUDA ,  Kazuyasu NAKAMURA

    发明人： Tomoaki NAKAGAWA ,  Sayaka HORI ,  Rinpei NIWA ,  Tsuguo KUBOTA ,  Kazuhiro MASUDA ,  Kazuyasu NAKAMURA

    IPC分类号： C07K16/28

    CPC分类号： C07K16/2812 ,  A61K2039/505 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92 ,  C07K2319/30 ,  G01N2333/70514

    摘要： An anti-CD4 antibody which binds to CD4, has a high affinity and has a high effector activity, such as an antibody-dependent cellular cytotoxicity (ADCC activity) or complement-dependent cellular cytotoxicity (CDC activity), is required for a disease relating to a CD4-expressing cell.The present invention can provide a monoclonal antibody or an antibody fragment thereof, which binds to a CD4 extracellular region with high affinity and also exhibits a high ADCC activity or a high CDC activity; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof or a diagnostic agent using the antibody or the antibody fragment thereof.

    摘要翻译： 与CD4结合的抗CD4抗体具有高亲和力并具有高效应活性，例如抗体依赖性细胞毒性（ADCC活性）或补体依赖性细胞毒性（CDC活性），涉及到疾病 到CD4表达细胞。 本发明可以提供以高亲和力结合CD4细胞外区域并且也表现出高ADCC活性或高CDC活性的单克隆抗体或其抗体片段; 产生抗体的杂交瘤; 编码抗体的DNA; 含有DNA的载体; 通过引入载体可获得的转化体; 使用杂交瘤或转化体生产抗体或其抗体片段的方法; 以及使用该抗体或其抗体片段的治疗剂或使用该抗体或其抗体片段的诊断剂。

    Anti-CD4 antibody
    30.
    发明授权
    Anti-CD4 antibody 有权
    抗CD4抗体

    公开(公告)号：US08399621B2

    公开(公告)日：2013-03-19

    申请号：US12647698

    申请日：2009-12-28

    申请人： Tomoaki Nakagawa ,  Sayaka Hori ,  Rinpei Niwa ,  Tsuguo Kubota ,  Kazuhiro Masuda ,  Kazuyasu Nakamura

    发明人： Tomoaki Nakagawa ,  Sayaka Hori ,  Rinpei Niwa ,  Tsuguo Kubota ,  Kazuhiro Masuda ,  Kazuyasu Nakamura

    IPC分类号： C07K16/00

    CPC分类号： C07K16/2812 ,  A61K2039/505 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92 ,  C07K2319/30 ,  G01N2333/70514

    摘要： An anti-CD4 antibody which binds to CD4, has a high affinity and has a high effector activity, such as an antibody-dependent cellular cytotoxicity (ADCC activity) or complement-dependent cellular cytotoxicity (CDC activity), is required for a disease relating to a CD4-expressing cell.The present invention can provide a monoclonal antibody or an antibody fragment thereof, which binds to a CD4 extracellular region with high affinity and also exhibits a high ADCC activity or a high CDC activity; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof or a diagnostic agent using the antibody or the antibody fragment thereof.

    摘要翻译： 与CD4结合的抗CD4抗体具有高亲和力并具有高效应活性，例如抗体依赖性细胞毒性（ADCC活性）或补体依赖性细胞毒性（CDC活性），涉及到疾病 到CD4表达细胞。 本发明可以提供以高亲和力结合CD4细胞外区域并且也表现出高ADCC活性或高CDC活性的单克隆抗体或其抗体片段; 产生抗体的杂交瘤; 编码抗体的DNA; 含有DNA的载体; 通过引入载体可获得的转化体; 使用杂交瘤或转化体生产抗体或其抗体片段的方法; 以及使用该抗体或其抗体片段的治疗剂或使用该抗体或其抗体片段的诊断剂。